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Chronic obstructive pulmonary disease (COPD) is charac-
terized by chronic and progressive airﬂow limitation that
is practically irreversible. COPD typically progresses over
time, with ever increasing symptom burden. Typically,
patients will experience breathlessness during normal
daily activities or even at rest, increased production and
purulence of sputum, overall health decline, and episodes
of prognostically grim exacerbations that require medical
intervention and sometimes hospitalizations.1–3
Worldwide, COPD is one of the leading causes of morbidity
and mortality.1 Prevalence and incidence of COPD is, at
least in some countries, exceptionally high, which makes
proper and comprehensive management of disease even
more important.3 It is projected that COPD will become the
third leading cause of death worldwide by 2020 so studies
of prevalence, pathophysiology, and management of this
disease are needed and in fact fully justiﬁed. But are they
properly valued? And even more important, are physicians
interpreting the obtained information in a proper manner?
Pathogenesis of COPD is far from being completely
elucidated, with many still poorly recognized pathophysi-
ological mechanisms and pathways.4–9 It is a multifaceted
syndrome with much clinical, cellular, and molecular
diversity.5,6,8,9 Paradoxically, its diagnosis, assessment of
severity, and currently available therapeutic options are
based primarily on the degree of airﬂow obstruction.1 COPD
also is a disease with chronic airway inﬂammation, which is
resistant to all known anti-inﬂammatory drugs with possible
exception of anti-inﬂammatory action of new PD4 antagonist
roﬂumilast.10 Inﬂammatory cells produce diverse mediators,
which can be occasionally detected in exhaled air of
patients with COPD. In last years many such biomarkers
were identiﬁed and their utility partially tested. Assessing
the value of speciﬁc biomarker is not an easy task.11
Among other prerequisites there should be reproducible
association between the biomarker and the outcome of
COPD management (diagnosis, risk stratiﬁcation; selection
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of therapy; monitoring disease progression, disease activity,
or response to therapy) conﬁrmed in multiple studies.
In recently published study,12 Stanojkovic with her team
examined markers of oxidative stress (malondialdehyde and
others) in 74 patients with severe COPD exacerbation and
in 41 healthy subjects. In patients all parameters were
assessed at two time points. Lucidly enough patients were
divided in two groups according the presence or absence of
ischemic heart disease. They found, that malondialdehyde
(MDA), advanced oxidation protein products (AOPP) and
total oxidant status (TOS) were increased and were higher at
discharge compared with admission and the control group.
Increased oxidative stress, elevated systemic inﬂammation
and decreased antioxidant defense were common in end-
stage disease and particularly in patients with concomitant
ischemic heart disease. Authors thus conﬁrmed results
of Bartoli et al., who demonstrated signiﬁcant inverse
correlation between MDA concentrations and FEV1.13 It has
to be admitted, that so far no single biomarker has been
able to gain wide acceptance, but some provide clinically
useful information. The evaluation of such biomarkers in
large studies would to become an object of intensive
investigation in the future14 and should maybe include
standard and routine laboratory biomarkers, like it was done
in heart failure (HF).15 Results of this study again speaks
in favor of complex inﬂammatory and pathophysiologically
interactions between COPD and HF and possibly, as stressed
in recently published paper, between COPD and other co-
morbidities as ischemic stroke or endocrinological disorders
as diabetes.16 This is an important message especially as
inhaled glucocorticoids accelerate the natural course of
diabetes.17
COPD frequently walks hand in hand with complex
comorbidity. In fact, HF, bronchial carcinoma or pneumonia
are the cause of many deaths in COPD patients, particularly
in those with mild or moderate disease.18 Although a
prevalent and deadly combination, concomitant COPD and
HF19–23 frequently remain unrecognized. Such a reluctance,
unfortunately, is not limited to daily practice but is evident
in international COPD guidelines, where comorbidites are
largely neglected.1 This translates back to clinical practice,
where beta blockers are withheld in many COPD patients
0954-6111$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
Chronic obstructive pulmonary disease status 2011: long walk home S5
with known cardiovascular disease. From analysis in the
journal24 and previous studies we can conclude that beneﬁts
of beta blockers outweigh any potential risk thus COPD
should not be regarded as contraindication for beta blocker
use any more.25–28
Management of COPD patients is a very complex task
indeed. Adherence to treatment is not optimal,29 but is
crucial for obtaining best management outcomes.30
Lately it become clear, that for successful management
to avoid potential problems that may occur after discharge
they should be identiﬁed during the discharge planning
process.31,32 Standardized, early screening to accurately
identify patients at risk for unmet needs after discharge
is critical to the development and implementation of a
quality discharge plan. The lack of time available to
hospital clinicians to assemble and interpret extensive and
complex information calls for improved methods to support
identifying patients at risk for poor outcomes, engaging
discharge planners efﬁciently and accurately, providing a
standardized assessment to identify and address continuing
care needs, and identifying patients who would beneﬁt from
post-acute care. This complex management process was
addressed also in the study of Farkas et al.,33 in which
investigators search for the evidence on the effectiveness of
a discharge coordinator in patients hospitalized due to acute
exacerbation of COPD. First information from this study is
already available and elegantly demonstrates the prognostic
importance of nutritional risk assessment.34 Further results,
primarily about main hypothesis, are eagerly awaited.
The quest for adequate management of COPD is far from
being complete. Answers to many questions are admittedly
not known; yet many were already quite properly answered.
Whether knowledge is translated into everyday routine is
another issue.
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